Skip to Content
Biotechnology

Here comes a more precise version of CRISPR

The first company to go after human disease with a more precise genome-editing tool called base editing, Beam Therapeutics, launched today.

The technology: DNA is made up of lots of combinations of base letters (we know them as A, C, G, and T). Base editing, developed by Harvard chemical biologist and Beam cofounder David Liu, is designed to target just one base out of billions within the genome.

CRISPR 2.0: The traditional CRISPR system cuts a whole gene—a sequence of different base letters—to make a break in DNA’s double-helix structure. Liu’s base editors directly convert a single base into another, changing the gene from the mutated to the corrected form. Last year, researchers in China reported that they used base editing to snip disease out of a human embryo, but the approach hasn’t been tried in a person yet.

Treating disease: Beam, which is also cofounded by CRISPR pioneer Feng Zhang, hasn’t said what diseases it will focus on. But in a press release, it said that base editing could be used to treat some of the most devastating genetic disorders.

Deep Dive

Biotechnology

This startup wants to copy you into an embryo for organ harvesting

With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.

This nanoparticle could be the key to a universal covid vaccine

Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.

How do strong muscles keep your brain healthy?

There’s a robust molecular language being spoken between your muscles and your brain.

The quest to show that biological sex matters in the immune system

A handful of immunologists are pushing the field to take attributes such as sex chromosomes, sex hormones, and reproductive tissues into account.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.